First-in-human study of AMG 193, an MTA-cooperative PRMT5 inhibitor, in patients with MTAP-deleted solid tumors: results from phase I dose exploration - Rodon, J.; Prenen, H.; Sacher, A.; Villalona-Calero, M.; Penel, N.; El Helali, A.; Rottey, S.; Yamamoto, N.; Ghiringhelli, F.; Goebeler, M.E.; Doi, T.; Postel-Vinay, S.; et al. (Annals of oncology, 2024)
Keywords: Adult; Aged; Dose-Response Relationship, Drug; Enzyme Inhibitors - administration & dosage; Enzyme Inhibitors - adverse effects; Enzyme Inhibitors - pharmacokinetics; Enzyme Inhibitors - therapeutic use; Female; Gene Deletion; Humans; Male; Maximum Tolerated Dose; methylthioadenosine phosphorylase; Middle Aged; MTAP; Neoplasms - drug therapy; Neoplasms - genetics; Neoplasms - pathology; non-small-cell lung cancer; pancreas cancer; PRMT5; protein arginine methyltransferase 5, synthetic lethality; Protein-Arginine N-Methyltransferases - antagonists & inhibitors; Protein-Arginine N-Methyltransferases - genetics; Purine-Nucleoside Phosphorylase - antagonists & inhibitors; Purine-Nucleoside Phosphorylase - genetics; Pyrazoles; Pyrimidines - administration & dosage; Pyrimidines - adverse effects; Pyrimidines - pharmacokinetics; Pyrimidinones; methylthioadenosine phosphorylase; PRMT5; MTAP; pancreas cancer; protein arginine methyltransferase 5, synthetic lethality; non-small-cell lung cancer